Shadbad et al. discussed the potential of Programmed Death-Ligand 1 (PD-L1)-inhibiting microRNAs, delivered via biomimetic carriers guided by single-cell sequencing, to target triple-negative breast cancer by downregulating PD-L1, enhancing immune responses, and inhibiting tumor growth [36]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.